For PAH Treatment, Mylan Launches Tadalafil Tablets, 1st Generic...
Aug 22, 2018 · “Mylan has a strong history of leading the way in creating important access to generic medicines, and we’re excited to continue that tradition by offering the first generic to Adcirca Tablets,” Heather Bresch, CEO of Mylan, said in a press release.. “Mylan offers more than 650 products in the U.S., and the addition of Tadalafil Tablets strengthens our …
Pulmonary Arterial Pressure Above 30 mmHg Linked to Increased...
Jul 8, 2019 · An estimated right ventricular systolic pressure (eRVSP) — a measure of the pressure inside the artery that supplies blood to the lungs (pulmonary artery) — greater than 30.0 mmHg is related to an increased risk of mortality in patients with pulmonary hypertension (PH), according to a new Australian study.
PAH symptom discordance with patients, physicians tied to worse...
Dec 20, 2024 · In PAH, high blood pressure in the blood vessels that carry blood from the heart to the lungs results in symptoms like shortness of breath, fatigue, and chest pain. The disease can make even simple activities, like walking or climbing stairs, increasingly difficult and negatively impacts patients’ quality of life.
Winrevair 'overwhelming' at treating advanced PAH in Phase 3 trial
Nov 27, 2024 · These top-line findings in the ongoing ZENITH trial (NCT04896008), testing the Merck treatment against a placebo while on background therapy, led an independent data monitoring committee to recommend the trial be stopped early. All enrolled patients now are invited to enter the open-label SOTERIA (NCT04796337) extension study and be …
Oxygen-sensing protein is possible therapeutic target in PAH: Study
Dec 16, 2024 · An oxygen-sensing protein called hypoxia-inducible factor-1alpha, or HIF-1alpha, may contribute to worsening pulmonary arterial hypertension (PAH) and is a possible therapeutic target for people with this rare type of pulmonary hypertension, a study by …
License pact for L606, potential long-acting version of Tyvaso...
Oct 9, 2024 · Approved treatments for people with PH-ILD lacking in many countries. In a previous Phase 1 study (NCT04041648) assessing L606’s pharmacokinetics — its movement into, through, and out of the body — in healthy adults, the treatment showed therapeutic levels for up to 12 hours, with a blood plasma peak concentration seven times lower than Tyvaso, the company reported.
MicroRNA in blood could be PAH marker in congenital heart disease
Nov 22, 2024 · The study, “ Expression and Diagnostic Value of miR-3591-5p in Patients with Congenital Heart Disease-Associated Pulmonary Arterial Hypertension,” was published in Lung. PAH is marked by high blood pressure in the vessels that carry blood through the lungs. People with congenital heart disease (CHD), a broad category that encompasses problems with heart structure or function from birth ...
Cereno Scientific secures loan financing to advance CS1 for PAH
Nov 15, 2024 · The financial agreement comes on the heels of top-line data from the Phase 2a CS1-003 trial (NCT05224531), which was designed to evaluate the safety and preliminary efficacy of CS1 in addition to standard of care in 25 adults with PAH.Participants were randomly assigned to receive one of three daily oral doses (480 mg, 960 …
Funding to advance novel PAH treatment from Australian scientists
Oct 23, 2024 · That funding came from Biocurate, a venture led by the University of Melbourne and Monash that aims to help translate promising treatment approaches from the lab into medicines that can be used by people. Awarded from Biocurate’s Proof of Concept (POC) Fund, the funding is expected to help the researchers identify …
Study IDs metabolites, genes as potential PAH diagnostic markers
Dec 18, 2024 · The researchers noted that these three genes are involved in some of the same biological pathways as the five metabolites. Among shared biological processes were immune response regulation and inflammation (kynurenine, tryptophan, and MAPK6), as well as cell growth (spermine and SLC7A11).. The scientists stressed that this study was based mainly on data from a small number of patients, so ...